Basel, Switzerland
Basel, Switzerland

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales among the world-wide industry in 2013.Novartis manufactures such drugs as clozapine , diclofenac , carbamazepine , valsartan and imatinib mesylate . Additional agents include cyclosporin , letrozole , methylphenidate , terbinafine , and others.In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations the International Federation of Pharmaceutical Manufacturers and Associations , and the Pharmaceutical Research and Manufacturers of America . Wikipedia.


Time filter

Source Type

Patent
Novartis | Date: 2017-07-05

An ophthalmic endo-illumination system (206) includes a light source that produces a light beam (305), a fiber port that receives an optical fiber (310), a condenser (302) that couples at least a portion of the light beam into the optical fiber received at the fiber port, and a beam splitter (304) disposed between the fiber port and the condenser. The beam splitter is configured to receive the light beam from the condenser and split the light beam into a first beam (312) which is coupled to the optical fiber and a second beam (314) which is coupled to a monitoring fiber (306). An optical sensor (308) is provided to detect an amount of the second beam output from the monitoring fiber. The coupling efficiency of the first beam coupled into the optical fiber may be determined based on the amount of the second beam output from the monitoring fiber.


The present invention relates to a method for measuring at least one inhalation flow feature in an inhaler (1), wherein a capsule (4) containing a formulation is located in the inhaler, the method comprising the steps of sensing an impact feature relating to impacts of the capsule on the inhaler and correlating the impact feature to at least one inhalation flow feature. The present invention also relates to an inhaler adapted to aerosolize a formulation contained in a capsule, wherein the inhaler comprises a sensor (16) for sensing an impact feature relating to impacts of the capsule on the inhaler and a processor (18) for correlating the impact feature to at least one inhalation flow feature. The present invention also relates to a system comprising an inhaler adapted to aerosolize a formulation contained in a capsule and a computing device (354) external of the inhaler, wherein the inhaler comprises a sensor for sensing an impact feature relating to impacts of the capsule on the inhaler and a data-receiving-transmitting means to receive and transmit data from and to the external computing device, wherein the external computing device also comprises data-receiving-transmitting means to receive and transmit data from and to the inhaler, wherein the inhaler and/or the external computing device comprises processing means for correlating the impact feature to at least one inhalation flow feature.


The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3- carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.


The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.


Patent
Novartis | Date: 2017-04-11

This invention relates to methods employing IL-1-Ligand/IL-1 receptor disrupting compounds (herein referred to as IL-1beta Compounds); such as small molecular compounds disrupting IL-1 ligand-IL-1 receptor interaction, IL-1 antibodies or IL-1 receptor antibodies, e.g. IL-1 binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1 binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1 ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.


The present invention provides methods of site-specific labeling of antibodies, using proteins having 4-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (peptide tags) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.


The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as ANGPTL4), and pharmaceutical compositions and methods of treatment comprising the same.


The invention is related to a method for producing silicone hydrogel contact lenses with having a stable coating thereon. A method of the invention comprises a water-based coating process (step) for forming a relatively-stable base coating of a homo- or copolymer of acrylic acid or C1-C3 alkylacrylic acid onto a silicone hydrogel contact lens made from a lens formulation comprising from about 35 % to about 60 % by weight of N-vinylpyrrolidone.


Patent
Novartis and University of Pennsylvania | Date: 2017-07-26

The invention relates, in part, to a method of treating a subject comprising administering to the subject a low, immune enhancing of a mTOR inhibitor and an immune effector cell engineered to expres a CAR.


Patent
Novartis and University of Pennsylvania | Date: 2017-06-21

The present disclosure relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family a-receptor 4 (GFRa4).

Loading Novartis collaborators
Loading Novartis collaborators